Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
10.1056/nejmoa1810858 · doi-reference
Adjuvant dabrafenib plus trametinib in stage III BRAF-MUTATED MELAnoma
10.1056/nejmoa1708539 · doi-reference
PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer
10.1056/nejmoa2201445 · doi-reference
Trastuzumab emtansine for residual invasive HER2-positive breast cancer
10.1056/nejmoa1814017 · doi-reference
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer
10.1016/s0140-6736(04)17666-6 · doi-reference
From tissue-agnostic to N-of-one therapies: (R)evolution of the precision paradigm
10.1016/j.trecan.2020.08.009 · doi-reference
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study
10.1038/s41698-021-00159-2 · doi-reference
Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2/3 amplification, overexpression, or mutation: results from the TAPUR study
10.1200/po.22.00609 · doi-reference
Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the targeted agent and profiling utilization registry (TAPUR) Study
10.1200/jco.20.02923 · doi-reference
Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer
10.1056/nejmoa2107322 · doi-reference
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results
10.1200/jco.2023.41.17_suppl.lba3000 · doi-reference
National cancer institute combination therapy platform trial with molecular analysis for therapy choice (ComboMATCH)
10.1158/1078-0432.ccr-22-3334 · doi-reference
Rational combinations of targeted cancer therapies: background, advances and challenges
10.1038/s41573-022-00615-z · doi-reference
Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations
10.1016/j.ccell.2021.12.004 · doi-reference
Functional precision cancer medicine-moving beyond pure genomics
10.1038/nm.4389 · doi-reference
Germline variants in targeted tumor sequencing using matched normal DNA
10.1001/jamaoncol.2015.5208 · doi-reference
Germline analysis from tumor-germline sequencing dyads to identify clinically actionable secondary findings
10.1158/1078-0432.ccr-16-0015 · doi-reference
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol
10.1093/annonc/mdw018 · doi-reference
Global Inequities in precision medicine and molecular cancer research
10.3389/fonc.2018.00346 · doi-reference
Think globally, act locally: globalizing precision oncology
10.1158/2159-8290.cd-22-0024 · doi-reference
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
10.1038/s41591-020-1063-5 · doi-reference
Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study
10.1002/ijc.31091 · doi-reference
Genomic landscape and clinical utility in Korean advanced pan-cancer patients from prospective clinical sequencing: K-MASTER program
10.1158/2159-8290.cd-21-1064 · doi-reference
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group
10.1136/ijgc-2022-003425 · doi-reference
A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients
10.1093/jamiaopen/ooz045 · doi-reference
Developing a virtual equity hub: adapting the tumor board model for equity in cancer care
10.1093/oncolo/oyac069 · doi-reference
I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy
10.1038/clpt.2009.68 · doi-reference
Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 Trial
10.1001/jamaoncol.2019.6650 · doi-reference
When should tumor genomic profiling prompt consideration of germline testing?
10.1200/jop.19.00201 · doi-reference
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
10.1016/j.annonc.2022.09.159 · doi-reference
Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer
10.1056/nejmoa2105215 · doi-reference
Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration
10.1200/jco.20.01035 · doi-reference
Olaparib for metastatic castration-resistant prostate cancer
10.1056/nejmoa1911440 · doi-reference
Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer
10.1056/nejmoa1903387 · doi-reference
FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer
10.1002/onco.13551 · doi-reference
Olaparib for metastatic breast cancer in patients with a germline BRCA mutation
10.1056/nejmoa1706450 · doi-reference
Overall Survival with osimertinib in resected EGFR-mutated NSCLC
10.1056/nejmoa2304594 · doi-reference
Abemaciclib combined with endocrine therapy for the adjuvant treatment of hr+, her2-node-positive, high-risk, early breast cancer (monarchE)
10.1200/jco.20.02514 · doi-reference
Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience
10.1002/1878-0261.13202 · doi-reference
Precision oncology: the UC San Diego Moores Cancer Center PREDICT experience
10.1158/1535-7163.mct-15-0795 · doi-reference
